French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Monday that it has acquired exclusive global rights, outside Greater China, to develop, manufacture, and commercialise SIM0613, an antibody-drug conjugate (ADC) targeting the LRRC15 protein.

Developed via Simcere Zaiming's proprietary ADC platform, SIM0613 is designed for enhanced tumour penetration and differentiated anti-tumour activity in solid tumours with the highest unmet needs. According to Ipsen, it has shown robust tumour regressions in multiple in vivo preclinical models.

The programme is expected to enter Phase I clinical development in the second half of 2026.

Under the agreement, Simcere Zaiming may receive up to USD1.06bn in upfront, development, regulatory, and commercial milestone payments, as well as tiered royalties on sales. Ipsen will assume responsibility for all activities outside Greater China, including manufacturing following tech transfer, Investigational New Drug submissions, and clinical trial applications.